During an appearance on CBS News Sunday, Pfizer CEO Albert Bourla said that Americans would need a fourth dose of a COVID-19 vaccine to fend off future variants of the virus. Speaking with anchor ...

NEW YORK - The emergence of the omicron variant has renewed fears of the novel coronavirus developing mutations that would allow it to evade existing vaccines, but the companies Pfizer and BioNTech ...

A Pfizer-BioNTech Covid-19 booster shot appears to provide strong protection against the omicron variant, while the initial two-dose vaccine may be insufficient to prevent infection, the companies ...

About 90 percent of people fully inoculated by the Pfizer-BioNTech vaccine are well protected from variants of the novel ...

Newly released data from Pfizer/BioNTech’s ongoing study of their COVID-19 vaccine suggests it is effective at preventing serious symptoms and death at least six months after vaccination. The ...

WASHINGTON - Pfizer said Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's ...

CHICAGO (Reuters) - After developing and rolling out COVID-19 vaccines at record speed, drugmakers are already facing variants of the rapidly-evolving coronavirus that may render them ineffective, a ...

Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. A story’s inclusion in ...

NEW YORK - The CEO of pharmaceutical giant Pfizer said during a televised interview Thursday that people will "likely" need a third dose of the COVID-19 vaccine. CEO Albert Bourla told CNBC that the ...